PRNewsWire
08 Jun 2026, 00:10 UTC · 12h ago
Story key points
3 claims · impact-rated
ASC30 Phase II results showed dose-dependent weight reductions up to 7.7% at 13 weeks with a better GI tolerability profile than orforglipron. — Positive Phase II human data and a superior safety profile compared to a known competitor (OFG) significantly derisk the lead candidate.
+0.60ASC30 demonstrated 2- to 3-fold greater potency and 5-fold higher oral exposure than orforglipron in in vitro and non-human primate studies. — Stronger pharmacological potency suggests a competitive edge in the crowded oral GLP-1 market.
+0.40Preclinical data for ASC39 showed a 9.9% body weight reduction in rat models and high selectivity for the amylin type 1 receptor. — Positive early-stage data expands the company's obesity pipeline, though preclinical results are less predictive than human trials.
+0.30Ticker attribution
Continue reading
6 related stories
Top 1 mover · tap to explore
Model heads
The company presented positive clinical and preclinical data for its obesity drug candidates ASC30, ASC37, and ASC39.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
3 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Seeking Alpha
6h ago
